Intuitive Surgical, headquartered in Sunnyvale, California, provides robotic-assisted surgical solutions and employs 13,676 staff. Its products include the da Vinci surgical system and Ion endoluminal system for minimally invasive procedures.
Based on our analysis, Intuitive Surgical has received an overvalued rating of 1 out of 5 stars from Cashu. Several key financial ratios highlight concerns regarding the company's valuation relative to its sector.
The Price-to-Earnings (PE) Ratio for Intuitive Surgical stands at an elevated 73.68, significantly higher than the sector average of 14.18. A high PE ratio may suggest that the stock is overvalued or that investors are expecting high growth rates, which may not be sustainable.
Additionally, the Price-to-Book (PB) Ratio is reported at 11.25, while the sector average is just 2.71. This disparity indicates that investors are paying much more for each dollar of book value compared to other companies in the sector, raising questions about the stock's intrinsic value.
While Intuitive Surgical shows strong profitability with a Net Profit Margin of 27.81, significantly outperforming the sector's -137.57, the high valuation metrics overshadow this positive aspect. Investors may overlook that a strong net profit margin alone does not justify the inflated valuation ratios.
Furthermore, the Return on Equity (ROE) Ratio of 14.05 is commendable but still raises concerns when weighed against the sector's -76.41. Similarly, the Return on Assets Ratio for Intuitive Surgical is 12.39, compared to -47.59 for the sector. Despite these positive ratios, the overall high valuation signals that the stock may not be a prudent investment at current levels.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!